Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
© Shutterstock

Image courtesy of Shutterstock

Applications are invited for the 2016 George Herbert Hunt Travelling Scholarship to support travel abroad for clinical study or research from graduates of the Oxford University Medical School.

The scholarship is of the value of about £4,000 and may be held with another award.  This scholarship is offered in every second year.

Eligibility to apply:

Candidates must either have been admitted to the Degrees of Bachelor of Medicine and Bachelor of Surgery of the University of Oxford or have passed the First Examination for the Degree of Bachelor of Medicine of the University and hold a medical degree of another British university qualifying him or her to practise medicine.  Current medical students are not eligible to apply; an award can only be made to an Oxford medical graduate who fulfils the above criteria.

Candidates are required to submit:

  • A letter of application outlining why they wish to apply for the scholarship and details of their proposed period of study, including an undertaking that, if elected, they will travel abroad for a period of at least one month for the purpose of clinical study or research in medicine;
  • An estimate of the costs of the proposed period of clinical study or research;
  • A statement of their academic record/CV;
  • Two testimonials in support of the candidate/application.

The scholar will be required to complete his or her period of travel within twelve months from the date of election, and within a reasonable period thereafter to submit to the Secretary of the Medical School for the approval of the electors a detailed report of his or her tenure of the scholarship.  Payment of nine-tenths of the scholarship will be made shortly before the period of travel, and the remaining one-tenth following the approval of the report.  The election will be made on 8 April 2016.

Applications should be sent to Mrs Laura Morgan, Medical School Office, Academic Centre, Level 2, John Radcliffe Hospital, Headington, Oxford, OX3 9DU.  E-mail: laura.morgan@medsci.ox.ac.uk.

The closing date for applications will be 19 February 2016.

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.